Literature DB >> 10987850

Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy.

R H Swerdlow1, L I Golbe, J K Parks, D S Cassarino, D R Binder, A E Grawey, I Litvan, J P Bennett, G F Wooten, W D Parker.   

Abstract

Progressive supranuclear palsy (PSP) is a neurodegenerative movement disorder of unknown etiology. We hypothesized that mitochondrial DNA (mtDNA) aberration could occur in this disease and contribute to its pathogenesis. To address this we created transmitochondrial cytoplasmic hybrid (cybrid) cell lines expressing mitochondrial genes from persons with PSP. The presence of cybrid mtDNA aberration was screened for by biochemical assay of mitochondrial gene products. Relative to a control cybrid set, complex I activity was reduced in PSP cybrid lines (p<0.005). Antioxidant enzyme activities were elevated in PSP cybrid lines. These data suggest that mtDNA aberration occurs in PSP, causes electron transport chain pathology, and can produce oxidative stress. Further study of mitochondrial dysfunction in PSP may yield insights into why neurodegeneration occurs in this disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10987850     DOI: 10.1046/j.1471-4159.2000.0751681.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  27 in total

1.  POLG and PEO1 (Twinkle) mutations are infrequent in PSP-like atypical parkinsonism: a preliminary screening study.

Authors:  Matthis Synofzik; Julia Schicks; Karin Srulijes; Claudia Schulte; Franziska Schiele; Daniela Berg; Ludger Schöls
Journal:  J Neurol       Date:  2012-05-12       Impact factor: 4.849

Review 2.  The neurodegenerative mitochondriopathies.

Authors:  Russell H Swerdlow
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 3.  Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities.

Authors:  Judit M Perez Ortiz; Russell H Swerdlow
Journal:  Br J Pharmacol       Date:  2019-03-06       Impact factor: 8.739

Review 4.  Progressive supranuclear palsy: clinical features, pathophysiology and management.

Authors:  A Rajput; A H Rajput
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 5.  Progressive supranuclear palsy.

Authors:  K Tawana; D B Ramsden
Journal:  Mol Pathol       Date:  2001-12

6.  Relationship between uric acid levels and progressive supranuclear palsy.

Authors:  David M Brody; Irene Litvan; Steve Warner; David E Riley; Deborah A Hall; Benzi M Kluger; David R Shprecher; Christopher R Cunningham
Journal:  Mov Disord       Date:  2016-02-18       Impact factor: 10.338

Review 7.  Mitochondrial dysfunction as a therapeutic target in progressive supranuclear palsy.

Authors:  Vincent Ries; Wolfgang H Oertel; Günter U Höglinger
Journal:  J Mol Neurosci       Date:  2011-07-27       Impact factor: 3.444

Review 8.  Neurodegenerative diseases: neurotoxins as sufficient etiologic agents?

Authors:  Christopher A Shaw; Günter U Höglinger
Journal:  Neuromolecular Med       Date:  2007-11-06       Impact factor: 3.843

Review 9.  Clinical trials: past, current, and future for atypical Parkinsonian syndromes.

Authors:  Richard M Tsai; Adam L Boxer
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

10.  Mitochondrial toxins in Basal Ganglia disorders: from animal models to therapeutic strategies.

Authors:  P Bonsi; D Cuomo; G Martella; G Sciamanna; M Tolu; P Calabresi; G Bernardi; A Pisani
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.